ClinicalTrials.gg
Active, not recruitingNCT04758611ETCHES IUpdated Mar 18, 2026

The ETCHES I Study (Endovascular Treatment of Communicating Hydrocephalus With an Endovascular Shunt)

An interventional study of eShunt™ Implant in Hydrocephalus, Communicating and Hydrocephalus, sponsored by CereVasc Inc. Active, not recruiting at 1 site in Argentina. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by CereVasc Inc · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Oct 2020, registered Feb 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The eShunt™ System is a minimally invasive method of treating communicating hydrocephalus. The eShunt System includes a proprietary eShunt Delivery System and the eShunt Implant, a permanent implant deployed in a minimally invasive, neuro-interventional procedure. The eShunt Implant is designed to drain excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system.

Read the detailed description

This is a prospective, single-center, open label, single-arm pilot study of the eShunt System. The study population consists of patients with post-aneurysmal subarachnoid hemorrhage (SAH) treated for increased intracranial pressure (ICP) resulting in symptomatic hydrocephalus using an external ventricular drain (EVD) to facilitate CSF drainage and who cannot be "weaned" from the EVD following the hemorrhagic event.

The study will be performed a single site with up to 30 subjects who meet the inclusion and exclusion criteria for the study. Subjects will be evaluated every 30 days for the first 90 days following eShunt Implant deployment with standard neurological evaluation appropriate for patients with communicating hydrocephalus. In addition, follow-up will occur at 180 days, 12 and 24 months post-operatively and will include imaging in addition to the standard neurological evaluation.

02

Conditions studied

  • Hydrocephalus, Communicating
  • Hydrocephalus

Browse trials for

Keywords

  • eShunt
03

In context

Hydrocephalus

190 studies on the registry are indexed under Hydrocephalus; 52 are open to participants now.

This study's enrollment of 20 is below the median of 41 across 97 interventional studies indexed under Hydrocephalus.

Browse Hydrocephalus studies →

Lead sponsor

CereVasc Inc is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age > 18
  2. Subject provides (IC)
  3. Post-aneurysmal SAH with Hunt and Hess Grades I-IV with EVD in place with the need for a permanent CSF shunt determined through a failed EVD clamping trial defined as:

    1. Post-clamping ICP of > 20 cmH2O for 15 min, or
    2. Post-clamping ICP > 25 cmH2O for \< 15 min with patient intolerance to EVD clamping
    3. Post-clamping ICP >15 cmH2O for 15 min with radiographic evidence of ventriculomegaly
  4. Clinical signs and symptoms of communicating hydrocephalus
  5. Neurologically stable without evidence of severe vasospasm
  6. Pre-procedure MRI with gadolinium confirmation of IPS (inferior petrosal sinus) and CPA (cerebellopontine angle) cistern anatomy suitable for eShunt Implant deployment as confirmed by SSC (subject screening committee)
  7. Pre-procedure CT confirmation of no obstruction preventing CPA cistern access at target implant site (e.g., petrous bone) as confirmed by SSC

Exclusion criteria

Exclusion Criteria:

  1. Patient is in a state of unconsciousness or is unable to understand the information provided in the Form for this study
  2. Indication of obstructive hydrocephalus
  3. Presence of gross blood in CSF from EVD
  4. Pregnant
  5. Unwilling or unable to comply with follow up requirements
  6. Active systemic infection or infection detected in CSF
  7. \< 1 year
  8. or to heparin or radiographic contrast agents which cannot be adequately pre-medicated, desensitized or where no alternative is available
  9. Occlusion or stenosis of the internal jugular vein
  10. Venous distension in the neck on physical exam
  11. Atrial septal defect or patent foramen ovale identified on cardiac echocardiogram
  12. History of bleeding diatheses, coagulopathy or will refuse blood transfusion in cases of emergency
  13. Clearly antecedent stroke unrelated to post-aneurysmal SAH
  14. Patient is currently participating in another drug or device trial that could conflict with study data collection or follow-up
  15. Other medical illnesses that may cause the patient to be non-compliant with the protocol or confound data interpretation as determined by the study Investigator
  16. Presence of a deep vein thrombosis superior to the popliteal segment of the femoral vein
  17. (INR) or Partial Thromboplastin Time (PTT) results outside of normal range (INR 0.8-1.4; PTT 25-35 secs.)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Treatment Arm

    The Treatment Arm receives the eShunt implant

    Device: eShunt™ Implant

Interventions

  • DeviceeShunt™ Implant

    The eShunt™ Implant is designed to drain excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system as a minimally invasive treatment for communicating hydrocephalus.

    Also known as: eShunt™, eShunt™ System

06

What researchers measure

Primary outcomes

  1. Reduction in intracranial pressure (ICP)

    At 36-48 hours following eShunt Implant deployment and with EVD remaining clamped, an ICP assessment that demonstrates: 1) ICP below 20 cmH2O as measured by the EVD with no periods longer than 15 minutes above 20 cmH2O; and 2) No episodes of ICP, measured by EVD, above 25 cmH2O with associated subject symptoms

    Time frame: 36-48 hours following eShunt Implant deployment

Secondary outcomes

  1. Number of subjects requiring conversion to conventional CSF shunt

    Evaluate the need for CSF diversion by conventional CSF shunt insertion within the 24 months following eShunt Implant deployment

    Time frame: 24 months following eShunt Implant deployment

  2. Incidence of clinically significant abnormal laboratory test results

    Clinically significant changes from baseline laboratory test results will be summarized

    Time frame: 24 months following eShunt Implant deployment

  3. Incidence of clinically significant changes from baseline MRI imaging

    Clinically significant changes from baseline MRI images will be summarized

    Time frame: 24 months following eShunt Implant deployment

  4. Incidence of clinically significant changes from baseline CT imaging

    Clinically significant changes from baseline CT images will be summarized

    Time frame: 24 months following eShunt Implant deployment

Other outcomes

  1. Safety Endpoint: serious adverse events (SAEs)

    Evaluate for any device or procedure related serious adverse events (SAEs)

    Time frame: 24 months following eShunt Implant deployment

07

Study locations

1 site
08

References and documents

Publications

  • Heilman CB, Basil GW, Beneduce BM, Malek AM. Anatomical characterization of the inferior petrosal sinus and adjacent cerebellopontine angle cistern for development of an endovascular transdural cerebrospinal fluid shunt. J Neurointerv Surg. 2019 Jun;11(6):598-602. doi: 10.1136/neurintsurg-2018-014445. Epub 2019 Jan 9. PubMed 30626626 ↗
  • Lylyk P, Lylyk I, Bleise C, Scrivano E, Lylyk PN, Beneduce B, Heilman CB, Malek AM. First-in-human endovascular treatment of hydrocephalus with a miniature biomimetic transdural shunt. J Neurointerv Surg. 2022 May;14(5):495-9. doi: 10.1136/neurintsurg-2021-018136. Epub 2021 Dec 3. PubMed 34862267 ↗
  • Amllay A, Matouk CC. A Paradigm Shift in Hydrocephalus Management: The Promise of Endovascular Cerebrospinal Fluid Diversion. Cardiol Rev. 2025 Jul-Aug 01;33(4):294-297. doi: 10.1097/CRD.0000000000000886. Epub 2025 Mar 26. PubMed 40135887 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Jan 2026, 63 months.

Of 41 interventional studies with no phase under Hydrocephalus, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's 63 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2021
First posted
Feb 17, 2021
StartActual
Oct 1, 2020
Primary completionActual
Jan 7, 2026
CompletionEst.
Jan 7, 2028
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04758611
Lead sponsor
CereVasc Inc
Collaborators
AlvaMed, Inc., Bioscience Consulting, Inc., Simplified Clinical Data Systems, LLC
Responsible party
Sponsor
First posted
Feb 17, 2021
Start date
Oct 1, 2020
Primary completion
Jan 7, 2026
Completion
Jan 7, 2028 (estimated)
Last update
Mar 18, 2026

Study contacts

Pedro M Lylyk, MD
principal investigator · Clinica Sagrada Familia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion